Back to Search
Start Over
Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles
- Source :
- Acta Dermato-Venereologica; May2021, Vol. 101 Issue 5, p1-7, 7p
- Publication Year :
- 2021
-
Abstract
- The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients. Therefore, a retrospective study of 186 treatments with adalimumab, etanercept, and ustekinumab for psoriasis (341 patient-years) was performed. While PASI significantly and independently correlated with biomarkers of systemic inflammation (especially neutrophil-tolymphocyte ratio, C-reactive protein), the strengths were only weak-to-moderate and varied considerably inter-individually. A decrease in PASI indicated a neutrophil-to-lymphocyte ratio decrease and a C-reactive protein decrease or stable low margin C-reactive protein in = 80%. Sensitivity, specificity, and positive predictive value of PASI 0 and PASI 2.75 (optimal Youden Index) for low cardiovascular risk Creactive protein were 24%, 92%, 85%, and 62%, 61%, 76%, respectively. Performance was similar using absolute thresholds and PASI 100 or PASI 75, and overall worse for low cardiovascular risk neutrophil-tolymphocyte ratio and if psoriasis arthritis was present. In conclusion, PASI allows robust low-order estimates of systemic inflammation, but cannot substitute for laboratory biomarkers for more precise assessments. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00015555
- Volume :
- 101
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Acta Dermato-Venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 150508635
- Full Text :
- https://doi.org/10.2340/00015555-3814